Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Average Recommendation of "Buy" by Analysts

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) has received an average recommendation of "Buy" from the ten brokerages that are covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $24.44.

A number of analysts have weighed in on the company. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. The Goldman Sachs Group assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a "buy" rating and a $24.00 price objective for the company. Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Truist Financial started coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $21.00 to $23.00 in a report on Monday, May 12th.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the transaction, the executive vice president now directly owns 9,989 shares in the company, valued at $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.49% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Oarsman Capital Inc. bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $29,000. Golden State Wealth Management LLC acquired a new position in Teva Pharmaceutical Industries during the 1st quarter worth $39,000. New Age Alpha Advisors LLC bought a new stake in Teva Pharmaceutical Industries in the first quarter valued at about $43,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $44,000. Finally, Compagnie Lombard Odier SCmA acquired a new position in Teva Pharmaceutical Industries during the first quarter worth $54,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Up 2.0%

Teva Pharmaceutical Industries stock traded up $0.35 during trading hours on Thursday, hitting $17.67. The stock had a trading volume of 8,361,247 shares, compared to its average volume of 10,177,718. The stock's 50-day moving average price is $15.97 and its 200-day moving average price is $17.41. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries has a 12-month low of $12.47 and a 12-month high of $22.80. The stock has a market capitalization of $20.27 billion, a P/E ratio of -12.19, a price-to-earnings-growth ratio of 1.44 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The business's revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.48 EPS. Equities research analysts anticipate that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.